Advertisement

Search Results

Advertisement



Your search for The ASCO Post ,The ASCO Post matches 17098 pages

Showing 701 - 750


skin cancer
immunotherapy

RP1 Immunotherapy in Solid Organ Transplant Recipients With Skin Cancer

A novel oncolytic immunotherapy may show antitumor activity in solid organ transplant recipients with skin cancer, according to new findings presented by Migden et al at the American Association for Cancer Research (AACR) Annual Meeting 2024 (Abstract CT003). Background "Organ transplant recipients ...

kidney cancer
immunotherapy

Novel CAR T-Cell Therapy May Show Benefit in Patients With Advanced Clear Cell Renal Cell Carcinoma

The CD70-targeted allogeneic chimeric antigen receptor (CAR) T-cell therapy CTX130 may be effective in patients with advanced clear cell renal cell carcinoma, according to findings presented by Srour et al at the American Association for Cancer Research (AACR) Annual Meeting 2024 (Abstract CT002)...

multiple myeloma

Ciltacabtagene Autoleucel and Idecabtagene Vicleucel Approved by the FDA for Pretreated Patients With Multiple Myeloma

On April 5, the U.S. Food and Drug Administration (FDA) approved ciltacabtagene autoleucel (Carvykti) for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and...

gynecologic cancers
immunotherapy

Mirvetuximab Soravtansine Plus Pembrolizumab in Patients With Endometrial Cancer Subtype

The combination of the antibody-drug conjugate mirvetuximab soravtansine-gynx and the immune checkpoint inhibitor pembrolizumab showed notable activity in patients with recurrent or persistent microsatellite-stable endometrial cancer, according to new findings presented by Porter et al at the...

hepatobiliary cancer
immunotherapy

Can a Personalized Antitumor Vaccine Plus Pembrolizumab Improve Outcomes in Hepatocellular Carcinoma?

Adding a personalized antitumor vaccine to the PD-1 inhibitor pembrolizumab may be safe and about twice as effective at shrinking tumors in patients with hepatocellular carcinoma compared with pembrolizumab alone, according to new findings presented by Yarchoan et al at the American Association for ...

solid tumors

FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Solid Tumors

On April 5, the U.S. Food and Drug Administration (FDA) granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior systemic treatment and have no...

breast cancer

Judy C. Boughey, MD, on De-escalating Axillary Surgery After Chemotherapy for Breast Cancer

Judy C. Boughey, MD, of the Mayo Clinic, discusses findings from the I-SPY2 trial, which show that although the extent of residual disease and tumor biology in patients with breast cancer may impact outcomes, the type of axillary surgery after neoadjuvant chemotherapy does not (Abstract 3).

bladder cancer
immunotherapy
issues in oncology

Improving Adjuvant Treatment in Patients With Muscle-Invasive Urothelial Carcinoma

Two recent studies have offered new insights into the treatment of muscle-invasive urothelial carcinoma following cystectomy, according to findings presented by Powles et al and Galsky et al at the European Association of Urology Congress 2024. The research could allow physicians to target...

colorectal cancer
issues in oncology

Distinct Microbial Signature Uncovered in KRAS-Mutated Colorectal Cancer

Researchers have identified microbiota signatures that are associated with KRAS mutations in patients with colorectal cancer, according to a recent study published by Huang et al in Microbiology Spectrum. The findings suggest that gut microbes may serve as a noninvasive biomarker for subtypes of...

global cancer care
issues in oncology

American Cancer Society Releases Latest Global Cancer Statistics; Cancer Cases Expected to Rise to 35 Million Worldwide by 2050

The American Cancer Society (ACS) has released Global Cancer Statistics 2022, an update of the organization’s report on global cancer facts and trends. According to the findings, an estimated 20 million cancer cases were newly diagnosed in 2022 and 9.7 million people died from the disease...

Danicopan Approved as Add-On Therapy to Ravulizumab or Eculizumab for Extravascular Hemolysis in Adults With Paroxysmal Nocturnal Hemoglobinuria

On April 1, danicopan (Voydeya) was approved by the U.S. Food and Drug Administration (FDA) as add-on therapy to ravulizumab-cwvz or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH). VOYDEYA is a first-in-class, oral, Factor D...

lung cancer

Akhil G. Pachimatla, MD, on NSCLC: A Link Between Image-Based Measures of Obesity and Metabolic Pathways

Akhil G. Pachimatla, MD, of Roswell Park Comprehensive Cancer Center, discusses study findings showing that, in patients with non–small cell lung cancer (NSCLC), image-based adiposity measures show stronger correlations with gene-expression changes in these tumors than body mass index measures. Dr. ...

breast cancer

Kerollos N. Wanis, MD, PhD, on Risks for BRCA Mutation Carriers Treated With Breast-Conserving Therapy

Kerollos N. Wanis, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses a study in which he evaluated the risk of future ipsilateral and contralateral breast cancer events in a large cohort of patients with BRCA1 or BRCA2 mutations who chose breast conservation (Abstract 12).

leukemia

Feasibility of Ending Specialist Follow-up in Patients With Low-Risk CLL

A study published by Brieghel et al in Blood Advances showed that among patients in Denmark who had slow-growing chronic lymphocytic leukemia (CLL) with no symptoms and a low risk for ever needing treatment, those who stopped seeing their doctors for specialized follow-up had fewer hospital visits, ...

lung cancer
issues in oncology

Study Examines Shared Decision-Making Policies and Practices Around Lung Cancer Screening

A Medicare policy requiring shared decision-making between primary care physicians and patients regarding whether to proceed with lung cancer screening may require further examination, according to a recent study published by Kale et al in the Annals of Family Medicine. The findings indicated that...

solid tumors
issues in oncology
supportive care

Asking ChatGPT About Radiation Oncology Treatment

Researchers examined whether the artificial intelligence (AI)-based chatbot ChatGPT can help provide answers to patients with cancer regarding radiation oncology treatment, according to a recent study published by Yalamanchili et al in JAMA Network Open. Background Over 60% (n = 500,000) of...

issues in oncology

One in Five People With Cancer Participate in Clinical Research, New Study Finds

New findings authored by Joseph M. Unger, PhD, and colleagues in the Journal of Clinical Oncology using Commission on Cancer data showed that when all types of cancer research studies are considered, at least one in five people with cancer in the United States—or 21.9%—participate in some form of...

breast cancer
issues in oncology

Can TILs Help to Determine Outcomes in Triple-Negative Breast Cancer?

High levels of tumor-infiltrating lymphocytes (TILs) within the tumors of patients with early-stage triple-negative breast cancer may be associated with a lower risk of cancer recurrence and greater rate of survival, even without chemotherapy, according to a recent study published by Leon-Ferre et...

thyroid cancer
issues in oncology

Microwave Ablation vs Surgical Resection in Multifocal Papillary Thyroid Carcinoma

Microwave ablation may offer comparable progression-free survival rates and fewer complications in patients with papillary thyroid carcinoma compared with surgical resection, according to a recent study published by Zhao et al in Radiology. Background Papillary thyroid carcinoma—the most common...

breast cancer

Heather McArthur, MD, MPH, on Early-Stage High-Risk ER+/HER2− Breast Cancer: New pCR Results for Pembrolizumab and Chemotherapy

Heather McArthur, MD, MPH, of UT Southwestern Medical Center, discusses phase III findings from the KEYNOTE-756 trial, which shows that adding pembrolizumab to neoadjuvant chemotherapy increases pathologic complete response (pCR) rates in patients with early-stage, high-risk, estrogen...

prostate cancer
issues in oncology

Benefit of Prostate MRI Plus PSA Density Test in Patients Suspected of Having Prostate Cancer

Investigators have found that combining a prostate magnetic resonance imaging (MRI) scan with a prostate-specific antigen (PSA) density test may help diagnose clinically significant prostate cancer and avoid unnecessary biopsies, according to a recent systematic review and meta-analysis published...

solid tumors
hematologic malignancies
issues in oncology

Tuberculosis May Be Linked to Increased Risk of Various Cancer Types

The risk of certain types of cancer may be higher in patients currently or previously diagnosed with tuberculosis, according to new findings to be presented by Kim et al at the upcoming 2024 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) annual congress. Background...

breast cancer

Natália Polidorio, MD, PhD, on Triple-Negative Breast Cancer: Impact of Race on Treatment Efficacy

Natália Polidorio, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses findings on the impact of race on pathologic complete response in patients with early-stage triple-negative breast cancer who received neoadjuvant chemoimmunotherapy vs chemotherapy alone. Such targeted research may...

breast cancer

Treating DCIS: To Escalate or De-escalate?

There is much debate about the necessity of treating women with ductal carcinoma in situ (DCIS) with surgery or radiotherapy.1,2 It is disconcerting to many that patients with DCIS are treated in the same way as are women with early-stage invasive breast cancer. Many patients with DCIS have...

issues in oncology

Surveyed Oncologists’ Attitudes Toward Ethical Implications of AI in Cancer Care

Researchers surveyed oncologists for their perspectives on how artificial intelligence (AI) may be responsibly integrated into some aspects of cancer care as well as how to protect patients from the hidden biases of AI, according to a recent study published by Hantel et al in JAMA Network Open....

colorectal cancer

NAPRC-Accredited Hospitals vs Nonaccredited Hospitals: Proctectomy Outcomes

Hospitals accredited by the American College of Surgeons (ACS) National Accreditation Program for Rectal Cancer (NAPRC) may demonstrate lower mortality and complication rates in patients undergoing proctectomy compared with nonaccredited hospitals, according to a recent study published by Harbaugh...

cns cancers

Prolonged Use of Progestogens May Be Linked to Increased Risk of Brain Cancer

Prolonged use of selected progestogen agents may be associated with an increased risk of developing intracranial meningioma, according to a recent study published by Roland et al in the BMJ. Background Progestogens are similar to the natural hormone progesterone, which are widely used in menopausal ...

solid tumors
hematologic malignancies
issues in oncology

Malpractice Risk With Active Surveillance for Patients With Low-Risk Cancer

Investigators have assessed medical malpractice trends related to active surveillance as a treatment strategy across different types of cancers, according to a recent study published by Chang et al in the Annals of Surgery. Background Active surveillance is a less invasive approach that reserves...

leukemia
genomics/genetics

IKZF1 Genetic Variant May Contribute to Disparities in Risk of ALL in Pediatric Hispanic and Latino Patients

A genetic variant located on the IKZF1 gene may be responsible for disparities in the risk of acute lymphoblastic leukemia (ALL) among Hispanic and Latino children, according to a recent study published by de Smith et al in Cell Genomics. The findings offer insights into the causes of the disease...

multiple myeloma
issues in oncology

Novel Drug Combination in Multiple Myeloma

Researchers have found that venetoclax in combination with azacitidine may be effective at treating patients with multiple myeloma, according to a recent study published by Flanagan et al in Haematologica.  Background Despite recent advances in the treatment of multiple myeloma, the disease remains ...

gynecologic cancers

Matthew A. Powell, MD, on Endometrial Cancer: Overall Survival Update on Dostarlimab-gxly Plus Chemotherapy

Matthew A. Powell, MD, of the Washington University School of Medicine, discusses phase III findings from the RUBY trial, which shows dostarlimab-gxly plus chemotherapy improves overall survival in patients with primary advanced or recurrent endometrial cancer, regardless of mismatch repair status. ...

colorectal cancer
issues in oncology

Gut Microbiome Signatures May Help Unravel Disparities in Early-Onset Colorectal Cancer

The composition of the gut microbiome may reveal distinct signatures associated with race, ethnicity, and age of onset in patients with colorectal cancer, according to a recent study published by Hein et al in the Journal of Immunotherapy and Precision Oncology. The findings provide insights into...

colorectal cancer
issues in oncology

Subtype of Fusobacterium nucleatum May Be Linked to Colorectal Cancer Progression and Poor Outcomes

Researchers have found that a specific subtype of Fusobacterium nucleatum may be capable of growing within colorectal cancer, driving cancer progression, and leading to poorer outcomes following colorectal cancer treatment, according to a recent study published by Zepeda-Rivera et al in Nature. The ...

gynecologic cancers

Anne Knisely, MD, on Ovarian Cancer and the Implications of Detecting Residual Disease and ctDNA

Anne Knisely, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings showing that patients with ovarian cancer who undergo second-look laparoscopy and are found to have measurable residual disease (MRD) as well as circulating tumor DNA (ctDNA) after front-line therapy...

gynecologic cancers

Dostarlimab-Based Combinations in Advanced Endometrial Cancer

Statistically significant and clinically meaningful overall survival results from Part 1 and progression-free survival results from Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial in adult patients with primary advanced or recurrent endometrial cancer were presented in a late-breaking...

gynecologic cancers

FDA Approves Mirvetuximab Soravtansine-gynx for FRα-Positive, Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

On March 22, the U.S. Food and Drug Administration (FDA) approved mirvetuximab soravtansine-gynx (Elahere) for adult patients with folate receptor–alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic ...

breast cancer
issues in oncology

Low-Dose Radiotherapy Boost in Young Patients With Breast Cancer

Researchers have found that a low-dose radiotherapy boost in addition to whole-breast radiotherapy may prevent local recurrence in young patients with breast cancer, according to new findings presented by Bosma et al at the 2024 European Breast Cancer Conference (EBCC) (Abstract 4LBA) and...

breast cancer
issues in oncology

Response to Primary Systemic Therapy Could Dictate Whether Extensive Lymph Node Removal Is Needed in Patients With Breast Cancer

Extensive removal of the lymph nodes may be safely avoided in patients with breast cancer that has metastasized to the axillary nodes if treatment is tailored to their response to therapies such as chemotherapy prior to surgery, according to new findings presented by van Hemert et al at the 2024...

breast cancer
issues in oncology

Combined PET-MRI Scan Could Benefit Patients With Early-Stage Breast Cancer

A combined positron-emission tomography–magnetic resonance imaging (PET-MRI) scanning technique could improve the treatment of some patients with early-stage breast cancer, according to new findings presented by Di Micco et al at the 2024 European Breast Cancer Conference (EBCC) (Abstract 9) and...

bladder cancer

A Clinical Trial for Bladder Cancer Gave Me Back My Life

About 8 years ago, I was just a few years into menopause when I noticed blood in my urine. It wasn’t accompanied by pain, frequent urination, or any other troubling symptoms, so initially I wasn’t too concerned. But when I started passing pieces of tissue, I became alarmed and made an appointment...

issues in oncology
multiple myeloma

From Fatal to Fearless: How Patients Can Take Control of Their Disease and Fear Cancer Less

In 1996, at the age of 37, Kathy Giusti was diagnosed with the incurable blood cancer multiple myeloma and told she had about 3 years to live. In the mid-1990s, effective therapies for this second most common blood cancer were nearly nonexistent. Standard of care for myeloma consisted of oral...

gynecologic cancers

Mary McCormack, PhD, MBBS, on Locally Advanced Cervical Cancer: Results From the INTERLACE Trial

Mary McCormack, PhD, MBBS, of University College London Hospitals, NHS Foundation Trust, discusses the global health issue of cervical cancer and a way forward. Phase III findings from the GCIG INTERLACE trial showed that induction chemotherapy with weekly paclitaxel and carboplatin before...

FDA Approves Safety Labeling Changes Regarding DPD Deficiency for Fluorouracil Injection Products

On March 21, the U.S. Food and Drug Administration (FDA) approved safety labeling changes for fluorouracil injection products. This effort was a collaboration between the FDA’s Office of Generic Drugs and the Oncology Center of Excellence. Fluorouracil injection was initially approved in 1962. The...

breast cancer
issues in oncology

Addition of Atezolizumab to Adjuvant Chemotherapy in Triple-Negative Breast Cancer

The addition of atezolizumab to postsurgery chemotherapy may not benefit patients with triple-negative breast cancer, according to findings recently presented by McArthur et al at the 2024 European Breast Cancer Conference (EBCC; Abstract 1LBA). Background Triple-negative breast cancer is often...

breast cancer
supportive care
symptom management
pain management

Effect of Exercise on Symptom Burden and Quality of Life in Patients With Metastatic Breast Cancer

Taking part in an exercise program may improve pain, fatigue, and quality of life in patients with metastatic breast cancer, according to recent findings presented by Hiensch et al at the 2024 European Breast Cancer Conference (EBCC; Abstract 1). Background “Although there’s been quite a lot of...

hematologic malignancies
immunotherapy
issues in oncology

Incidence of Secondary T-Cell Malignancies Following CAR T-Cell Therapy

Investigators have found that second primary malignancies following chimeric antigen receptor (CAR) T-cell therapy were reported in 4.3% of CAR T-cell therapy adverse event reports submitted to the U.S. Food and Drug Administration’s (FDA) Adverse Event Reporting System, with T-cell malignancies...

breast cancer
immunotherapy

Updated Immune Classifier May Accurately Identify Patients With Triple-Negative Breast Cancer Who Are Unlikely to Respond to Immunotherapy

A novel genetic test may predict how patients with triple-negative early-stage breast cancer will respond to immunotherapy, according to new findings presented by Wolf et al at the 2024 European Breast Cancer Conference (EBCC) (Abstract 2LBA). The research may help patients who are unlikely to...

breast cancer
immunotherapy

Pembrolizumab May Improve Breast Cancer Outcomes Regardless of Age or Menopausal Status

The addition of the immunotherapy drug pembrolizumab to chemotherapy prior to and following surgery may lead to improved outcomes in patients with breast cancer regardless of their age or menopausal status, according to new findings presented by Cardoso et al at the 2024 European Breast Cancer...

gastroesophageal cancer

Fruquintinib Plus Paclitaxel Under Study as Second-Line Treatment of Gastroesophageal Cancer

The combination of the small molecule inhibitor of VEGFR fruquintinib and the chemotherapy paclitaxel presents a potential new second-line treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma, according to data presented during the ASCO Plenary Series: February...

W. Kimryn Rathmell, MD, PhD, Selected as 17th Director of the NCI

W. Kimryn Rathmell, MD, PhD, took the helm as the 17th Director of the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), on December 18, 2023. A renowned kidney cancer expert and influential leader in cancer research and patient care, Dr. Rathmell was selected by...

Advertisement

Advertisement




Advertisement